Every 8-K that Armata Pharmctcl (ARMP) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow ARMP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ARMP filings page.
Armata Pharmaceuticals reported second quarter 2026 results and provided an update on its bacteriophage pipeline. The company is preparing to initiate a pivotal Phase 3 superiority study of AP-SA02 for complicated Staphylococcus aureus bacteremia in the second half of 2026, following submission of the Phase 3 protocol to the FDA, completion of End-of-Phase 2 interactions, CMC progress, and FDA agreement on an Agreed Initial Pediatric Study Plan. AP-SA02 has Qualified Infectious Disease Product and Fast Track designations, and positive Phase 2a diSArm data were previously highlighted at IDWeek 2025.
For the quarter ended June 30, 2026, grant and award revenue was $2.5 million, up from $2.2 million a year earlier. Research and development expenses were $7.6 million and general and administrative expenses $5.2 million, resulting in a loss from operations of $10.3 million versus $6.8 million in 2025. Other income, net, was $84.5 million, primarily from a $91.0 million non-cash gain from the change in fair value of the Convertible Loan, partially offset by $6.6 million of interest expense. Net income was $74.1 million, or $2.02 per basic share and a $(0.27) loss per diluted share. Cash and cash equivalents were $24.0 million at June 30, 2026, up from $8.7 million at December 31, 2025, mainly reflecting a $25.0 million term loan, $2.4 million of at-the-market equity proceeds, and $1.2 million from stock option exercises, partly offset by cash used in operations.
Armata Pharmaceuticals, Inc. reported major progress advancing AP-SA02, its intravenously administered multi-phage therapy for complicated Staphylococcus aureus bacteremia, toward a planned Phase 3 superiority study intended to support a future Biologics License Application.
Armata highlighted submission of the complete Phase 3 protocol and comprehensive responses to all FDA End-of-Phase 2 comments, completion of four AP-SA02 engineering manufacturing runs, and plans to initiate the pivotal Phase 3 trial in the second half of 2026. The company also noted an additional $2.5 million continuation award from the U.S. Department of Defense, bringing total funding under that award to $28.7 million to support Phase 3 readiness, and announced the promotion of David House to Chief Financial Officer.
Armata Pharmaceuticals, Inc. promoted and appointed David House as Chief Financial Officer, effective July 17, 2026. House had been Senior Vice President, Finance and principal financial officer since August 2024 and will continue to report to the Chief Executive Officer.
Under a new employment letter, House receives an annual base salary of $371,315 and is eligible for a target annual bonus equal to 50% of base salary, with the percentage subject to future increases at the Board’s discretion. The compensation committee currently intends to grant him annual equity awards starting in 2026 with a grant date fair value of about $300,000, on terms consistent with other senior executives. If terminated without Cause or he resigns for Good Reason, he is eligible for 12 months of base-salary continuation, and time-based equity awards fully vest upon an involuntary termination occurring within one month before or 12 months after a Change in Control. The definition of “change in control” in Chief Business Officer Pierre Kyme’s agreement was also conformed to this standard.
Armata Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has agreed to an Initial Pediatric Study Plan (Agreed iPSP) for AP‑SA02, a bacteriophage therapy being developed as an adjunct treatment for complicated Staphylococcus aureus bacteremia in pediatric patients.
The Agreed iPSP is a regulatory requirement before submitting a Biologics License Application and sets a framework for evaluating patients up to 17 years of age, aligned with the adult indication. Under FDA requirements and the Pediatric Research Equity Act, pediatric studies will be deferred until safety and efficacy data are generated in adults in a planned Phase 3 program expected to start in the second half of 2026. After completion of the adult Phase 3 study, Armata plans a single multicenter, open‑label pediatric study to assess safety, tolerability and clinical response.
AP‑SA02, a fixed multi‑phage cocktail targeting methicillin‑sensitive and methicillin‑resistant S. aureus, has Qualified Infectious Disease Product and Fast Track designations. Positive Phase 1b/2a diSArm study results were previously presented, and Armata plans a Phase 3 superiority study in complicated bacteremia, anticipated to initiate in the second half of 2026.
Armata Pharmaceuticals, Inc. filed an amended report to update details about new director Dr. Daniel Gilmer. The amendment explains that, effective June 24, 2026, the Board appointed Dr. Gilmer to its Nominating and Corporate Governance Committee. He will receive a $5,000 cash retainer for this committee role under the 2026 non-employee director compensation program, with the amount pro-rated based on his appointment date. All other information from the original report about his appointment to the Board remains unchanged.
Armata Pharmaceuticals reported that it received an additional $2.5 million in non-dilutive funding from the U.S. Department of Defense to support its lead bacteriophage candidate, AP-SA02. This increases the total DoD award to $28.7 million, aimed at advancing AP-SA02 for adjunct treatment of complicated Staphylococcus aureus bacteremia caused by MSSA or MRSA.
The new funds are intended to support Phase 3 readiness activities. Armata plans to initiate a Phase 3 superiority study of intravenous AP-SA02 in complicated SAB in the second half of 2026. AP-SA02 has Qualified Infectious Disease Product and Fast Track designations and previously generated positive Phase 2a results in the diSArm study.
Armata Pharmaceuticals reported results from its annual shareholder meeting. Shareholders elected seven directors, each receiving about 28.3–28.5 million votes in favor, with relatively small withhold and broker non-vote totals.
Investors also approved, on a non-binding advisory basis, the compensation of the named executive officers with 28,547,283 shares voting for and modest opposition. Shareholders supported holding future advisory votes on executive pay every year, with 28,567,809 votes backing a one-year frequency. In addition, they ratified Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, by 29,842,514 votes in favor.
Armata Pharmaceuticals entered a new secured term loan agreement with Innoviva Strategic Opportunities for $25 million at a 14.0% annual interest rate, maturing on January 11, 2029, guaranteed by its domestic subsidiaries and secured by substantially all assets. The company also reported first quarter 2026 results: grant and award revenue was $0.8 million and research and development expenses were $6.1 million, reflecting continued investment in its AP‑SA02 bacteriophage program. Net loss widened sharply to $115.3 million, largely driven by a $101.1 million unfavorable change in the fair value of a Convertible Loan, while cash and cash equivalents declined to $4.8 million as of March 31, 2026. Armata highlighted FDA Qualified Infectious Disease Product and Fast Track Designation for AP‑SA02 and its goal to advance this candidate into a Phase 3 study in complicated S. aureus bacteremia.
Armata Pharmaceuticals announced that the U.S. Food and Drug Administration has granted Fast Track Designation to AP-SA02, its intravenous multi-phage therapy for complicated Staphylococcus aureus bacteremia, including MSSA and MRSA. This status is intended for serious conditions with unmet medical need.
Fast Track allows more frequent FDA interactions, rolling review of a future Biologics License Application, and potential eligibility for Accelerated Approval and Priority Review if supported by clinical data. Armata plans to advance AP-SA02 into a Phase 3 superiority study in complicated bacteremia, anticipated to begin in the second half of 2026, following positive Phase 1b/2a diSArm study results partially backed by a $26.2 million Department of Defense award.
Armata Pharmaceuticals, Inc. appointed Dr. Daniel B. Gilmer, 39, to its Board of Directors, effective April 24, 2026, to serve until the next annual shareholder meeting. He will receive the Company’s standard non-management director compensation, including a $40,000 annual cash retainer.
Dr. Gilmer is expected to receive a stock option to purchase 51,280 shares of common stock at the fair market value on the grant date, vesting in equal installments over three years under Armata’s 2016 Stock Incentive Plan. The Company also entered into a standard indemnity agreement with him and noted there are no related-party or Item 404(a) transactions.
Armata highlighted Dr. Gilmer’s extensive background at Pfizer, where he leads commercial quality across more than 50 U.S. brands and previously helped launch an FDA‑approved antiviral and diagnostics portfolio. His experience in antimicrobial resistance and bacteriophage therapeutics aligns with Armata’s late clinical-stage phage-based pipeline.
Armata Pharmaceuticals, Inc. has scheduled its 2026 annual meeting of stockholders for June 11, 2026 at 8:30 a.m. Pacific Time at its principal executive offices in Los Angeles, California. Stockholders of record at the close of business on April 17, 2026 will be entitled to receive notice and vote at the meeting.
The company has set 5:00 p.m. Pacific Time on April 12, 2026 as the deadline for receipt of stockholder proposals and director nominations submitted under Section 2.6 of its Amended and Restated Bylaws. Proposals and nominations must be delivered in writing to the Corporate Secretary at Armata’s principal executive offices and must comply with the advance notice provisions in the bylaws.
Armata Pharmaceuticals reported a sharp deterioration in results for the quarter and year ended December 31, 2025. Fourth-quarter grant revenue was $1.1 million, while research and development expenses fell to $6.1 million and general and administrative expenses were $3.4 million. The company recorded a $5.4 million impairment on vacated office and R&D space, contributing to a fourth-quarter operating loss of $13.8 million.
For full-year 2025, Armata posted a net loss of $173.8 million, compared with a $18.9 million net loss in 2024, driven largely by a $121.0 million non-cash loss from changes in fair value of a convertible loan and higher interest expense. Total liabilities rose to $295.5 million, resulting in a stockholders’ deficit of $218.6 million. Cash, cash equivalents and restricted cash were $14.1 million at year-end. In January 2026, Armata extended the maturity of multiple credit agreements to June 1, 2027 and lengthened warrant expirations. Its audited 2025 financial statements include an explanatory going concern paragraph. As of March 18, 2026, Armata had 36.6 million common shares outstanding.
Armata Pharmaceuticals reported that it will delay announcing its fourth quarter and full-year 2025 financial results, while still expecting to file its Form 10-K on or before March 31, 2026. At the same time, the company highlighted an End-of-Phase 2 meeting with the FDA that aligned on a development plan for AP-SA02 in complicated Staphylococcus aureus bacteremia.
Armata plans to initiate a rigorously designed Phase 3 superiority study of AP-SA02 later in 2026 and has received Qualified Infectious Disease Product (QIDP) designation from the FDA for this program. The company also acknowledged ongoing support from Innoviva and the U.S. Department of Defense for its bacteriophage therapy pipeline.
Armata Pharmaceuticals announced that the FDA has granted its intravenous S. aureus phage therapy candidate AP-SA02 Qualified Infectious Disease Product (QIDP) status for adjunct treatment of complicated bacteremia caused by MSSA or MRSA.
This QIDP designation provides five additional years of market exclusivity under the GAIN Act and makes AP-SA02 eligible for Fast Track consideration, priority review, and rolling review. Armata plans to request Fast Track designation and advance AP-SA02 into a planned Phase 3 superiority study in complicated S. aureus bacteremia, anticipated to start in the second half of 2026. Earlier Phase 1b/2a results were positive and development has been partially supported by a $26.2 million Department of Defense award.
Armata Pharmaceuticals updated key financing and governance arrangements with its principal shareholder Innoviva. The company amended four existing credit agreements with Innoviva Strategic Opportunities LLC to extend each loan’s maturity date to June 1, 2027, giving Armata more time before repayment is due.
The two parties also amended four existing warrant certificates held by Innoviva Strategic Opportunities LLC, pushing each warrant’s expiration date out to January 26, 2031. These warrants cover specific blocks of common stock, including 1,807,396 shares under a February 9, 2022 warrant and 4,285,935 shares under a March 17, 2021 warrant.
In addition, Armata, Innoviva and Innoviva Strategic Opportunities LLC modified their Second Amended and Restated Voting Agreement so that it now ends on the earlier of January 26, 2031 or approval by the U.S. Food and Drug Administration of any Armata product candidate for marketing and commercial distribution.
Armata Pharmaceuticals reported that it has received an End-of-Phase 2 written response from the U.S. Food and Drug Administration and plans to advance its intravenously administered Staphylococcus aureus bacteriophage product candidate, AP-SA02, into a Phase 3 clinical study. The planned trial will focus on patients with complicated S. aureus bacteremia, a serious bloodstream infection.
The company disclosed this update through a press release furnished as an exhibit, emphasizing that the information is being provided for informational purposes and is not deemed filed under securities laws. No financial results or transaction details are included in this report.
Armata Pharmaceuticals, Inc. entered into a Capital on Demand™ Sales Agreement with JonesTrading Institutional Services LLC to set up an at-the-market stock offering program. Under this arrangement, Armata may, at its discretion, offer and sell shares of its common stock with an aggregate offering price of up to $100,000,000 through JonesTrading as sales agent. Sales can be made on the NYSE American or other permitted markets and in negotiated transactions, with Armata paying JonesTrading a commission of up to 3.0% of gross sale proceeds and reimbursing certain legal expenses. Neither party is obligated to sell or purchase shares, and the program is limited by the amount registered on Armata’s existing Form S-3 shelf registration and the number of authorized but unissued shares.
Armata Pharmaceuticals, Inc. filed a current report to note that it has announced its financial results for the three and nine months ended September 30, 2025. The company released these results in a press release dated November 12, 2025, which is attached as Exhibit 99.1.
The company states that the information in this results announcement and the related exhibit is being furnished, not filed, under securities laws, and will not be incorporated by reference into any registration statement or other document under the Securities Act of 1933.
Armata Pharmaceuticals furnished an update on its bacteriophage program. The company announced positive results from its recently completed Phase 2a diSArm study of AP-SA02 as a potential treatment for complicated Staphylococcus aureus bacteremia, presented at IDWeek 2025.
The company furnished a press release as Exhibit 99.1 and posted the late‑breaking oral presentation delivered by Dr. Loren G. Miller on October 22, 2025, furnished as Exhibit 99.2. The materials were provided under Item 7.01 and are not deemed filed under the Exchange Act nor incorporated by reference into Securities Act filings.
Armata Pharmaceuticals announced it has entered a secured $15.0 million term loan with Innoviva Strategic Opportunities LLC, a subsidiary of Innoviva, Inc., identified in the filing as a principal shareholder. The Loan bears interest at 14.0% per annum and matures on January 11, 2029. Repayment is guaranteed by Armata's domestic subsidiaries and the Loan is secured by substantially all assets of the company and the subsidiary guarantors.
The credit agreement includes customary affirmative and negative covenants and representations, including financial reporting obligations and limits on indebtedness, liens, investments and distributions. It also contains customary events of default, including payment defaults, breaches, certain bankruptcy events, a defined "material adverse effect" and a material deviation from the companys operating budget. The company also furnished a press release disclosing its results for the three and six months ended June 30, 2025 as Exhibit 99.1.